Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
stromal cell-derived factor 1 mRNA
- Development stage
- Preclinical
- Lead developer
- Evincis Bio
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intralesional, Parenteral
01
Overview
Stromal cell-derived factor 1 (SDF-1) mRNA (EVI-200) is an investigational regenerative gene therapy being developed by Evincis Bio, in collaboration with East Carolina University, Johns Hopkins University, and the University of Maryland, for the treatment of erectile dysfunction (ED), particularly diabetic neurovascular ED. Delivered locally via intracavernosal injection using a novel PEGylated poly(disulfide amine) (PEG-PDSA) nanoparticle system, the therapy involves synthetic mRNA that encodes human SDF-1 (CXCL12). Once translated, the SDF-1 protein acts as an agonist for the CXCR4 and ACKR3 receptors, triggering endogenous tissue repair pathways, promoting neurogenesis, angiogenesis, and muscle regeneration, and ultimately restoring erectile function by addressing the underlying neurovascular damage.
- Other names
- CXCL12 mRNACXCL-12 mRNACXCL 12 mRNASDF-1 mRNASDF1 mRNASDF 1 mRNAstromal cell-derived factor-1 mRNAstromal derived factor-1 mRNA
02
Targets
CXCR7 (CXC chemokine receptor 7)CXCL12 (C-X-C motif chemokine ligand 12)CXCR4 (C-X-C motif chemokine receptor 4)Neuraminidase
Beyond the preview
Go deeper on stromal cell-derived factor 1 mRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on stromal cell-derived factor 1 mRNA.